News from pharmaceutical companies and other related healthcare organizations
MAR002 is an early, promising development: a new take on a proven strategy, with the potential for stronger IGF-1 control and dramatically less frequent dosing. At the same time, it’s important to keep expectations grounded. The drug is still investigational. It is not approved, not yet available outside clinical trials, and a larger patient study is needed to confirm what the early data suggest.
The Corcept Therapeutics “Grace Study”, designed to evaluate the benefits and side effects of a new medication for people with endogenous Cushing’s syndrome, continues full steam ahead. The company recently announced the availability of new
Kudos to Pfizer’s new series on patient support. The first one features critical advice on emotional and mental help support! The materials provide valuable content given the importance of mental health issues to acromegaly patients.
From the desk of J D Faccinetti – co-founder – The company recently kicked off a phase 3 trial for their new nonpeptide oral drug for acromegaly and announced the dosing of their first acromegaly
Camurus AB, a pharmaceutical company based in Lund, Sweeden, is currently recruiting volunteers for two clinical trials on the long-term safety and efficacy of an octreotide subcutaneous depot to treat acromegaly. This new treatment offers
With the recent approval and commercial launch of MYCAPSSA®, Chiasma delivers the first and only oral somatostatin analog to treat acromegaly. The research showed 58% of patients maintained normal IGF-1 levels with the new oral
From a Crinetics Pharmaceutical press release: Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced that the
In a recent press release, Recordati Rare Diseases announced the results from a Phase III study of Isturisa® (Osilodrostat) published in Lancet Diabetes and Endocrinology. “The exciting data, published today, underscore the efficacy and safety
In a recent press release, Recordati Rare Diseases Inc., a biopharmaceutical company committed to developing therapies for rare disease communities of the United States, announced the full availability of Isturisa® for the treatment of adult
From the editors’ desk – A recent Endocrine Web article by Kimberly B. Bjugstad Ph.D. highlights a new oral octreotide drug for Acromegaly. The drug currently is on an FDA Phase III trial, referred to as OPTIMAL,
In this podcast, Dr. Lewis Blevins discusses a new drug for Cushing’s disease recently approved in the US.
In a press release today, San Diego, California based Crinetics Pharmaceuticals reports positive results from their Phase Two trial of PALTUSOTINE (the former CRN00808). This is a new oral medication to treat acromegaly and neuroendocrine